Skip to main content

Table 6 Total treatment costs for with and without SEB scenarios in year 3

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

Patient type (CKD stage) Treatments for anemia Year 3 total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 35,043,965 26,219,895
Long acting ESA (SC) 36,453,512 27,274,518
Epoetin SEB - 7,807,525
Stage V Short acting ESA (SC) 28,414,572 21,259,783
Long acting ESA (SC) 19,676,765 14,722,155
Short acting ESA (IV) 116,734,773 87,340,957
Long acting ESA (IV) 81,175,581 60,735,569
Epoetin SEB - 26,863,384
Total 317,499,168 272,223,786
  1. SEB = subsequent entry biologic; CKD = chronic kidney disease; ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.